YISHENG PHARM(002566)2025-05-27 08:40Group 1: Company Performance - In 2024, the company achieved a revenue of ¥668,468,926, a decrease of 21.69% compared to the previous year [2] - The net profit attributable to shareholders was ¥52,086,058.77, down 45.02% year-on-year [2] - The net profit after deducting non-recurring gains and losses was ¥27,064,642.33, reflecting a decline of 64.33% compared to the previous year [2] - The decline in performance is attributed to the impact of macroeconomic conditions and industry policies on production and sales volumes [2] Group 2: Business Strategy and Market Promotion - The company focuses on building a complete ginseng industry chain, leveraging traditional culture and modern technology [3][4] - Different sales channels are established for various products, including a dedicated management structure for pharmaceuticals [3] - The company actively promotes its products through academic marketing and is expanding into the OTC market [3] - Health foods and cosmetics are primarily sold through franchised beauty salons, with efforts to integrate online and offline sales channels [3] Group 3: Research and Development Plans - In 2025, the company plans to increase R&D investment and establish a special R&D fund for key projects [4] - Recruitment efforts will focus on attracting experienced and innovative R&D talent through campus and social recruitment [4] - The company aims to strengthen partnerships with universities and research institutions to enhance collaborative research efforts [4] Group 4: Shareholder Value and Market Position - The company is committed to enhancing core competitiveness to create value for shareholders [4] - Strategies will be dynamically assessed based on market conditions, business development, and shareholder needs [4]